Executive Management Team
Sean C. Morris, Chief Executive Officer
Sean is the Chief Executive Officer for Pulse Therapeutics and handles the day to day management of the companies’ exceptional human talent. With nearly 20 years of experience in the medical device sector, Sean also sets the strategic direction and ensures that the company is well capitalized in order to execute the company objectives. Sean handles the companies’ external relationships with Key Opinion Leaders, investors and other company stakeholders and also manages all commercial and marketing-related programs. Prior to joining Pulse in December of 2013, Sean was the Founder and CEO of Veniti, a venous disease start up based in St. Louis, MO. Sean started the company in 2009 and brought the company through the European approval and launch of the Vici Venous Stent™. While at the helm as CEO for Veniti, Sean successfully raised in excess of $30M to fund operations. Prior to Veniti, he held various executive positions with AngioDynamics, his last post being the Sr. Vice President and General Manager of the Peripheral Vascular Division where he had P&L responsibility of an enterprise exceeding $150M in annual sales. Sean holds a Bachelor of Science degree in Biochemistry from Missouri State University in Springfield, MO.
Francis “Duke” Creighton, Ph.D, Founder & Chief Technical Officer
Duke is the founder of Pulse Therapeutics and the inventor of the technology. Duke has been involved in startup-to-post-IPO medical-robotic and drug-delivery companies for over twenty years and possesses a deep expertise in cardiovascular and stroke therapies. His roles in the company include overseeing the technology programs and managing relationships with regulators, CROs, and HRECs to ensure successful trial enrollment resulting in a compelling data package. His responsibilities include developing and maintaining strong clinical relationships at thought-leading worldwide sites, including US, Europe, and Australasia. In addition to overseeing GMP, GLP, IEC 60601 compliance, he manages the worldwide IP plan with fast-approval strategy for core system & method patents, resulting in multiple accelerated US approvals. Duke is also the author of successful SBIR grant proposals to the NIH and was the author of the 1st-Place business plan for the 2011 St. Louis Business Plan Competition. Prior to Pulse Therapeutics, Duke served as Senior Director of R&D at Stereotaxis, where over the course of fifteen years, he designed the current commercial robotic technology platform. To date, he is responsible for over 30 patents. During his time at Stereotaxis, he worked closely with the CEO, President, and Board of Directors to develop new technologies, techniques, and devices for precise EP catheter and IC/INR guide-wire navigation. Duke received his Ph. D. in Physics (emphasis in advanced medical robotics) from the University of Virginia in 1996. Duke also continues to serve as a technology reviewer for the NIH, NCI, and NSF.
Peggy S. Stohr, Chief Financial Officer
Peggy serves or has served as the Chief Financial Officer for several development stage companies since 2009, including EndoStim, Pulse Therapeutics and Yurbuds. From 1999 to 2009, she held various positions at Stereotaxis, Inc. (NASDAQ:STXS), most recently as Vice President – Administration and Controller where she was responsible for all aspects of financial reporting (including Sarbanes Oxley compliance), human resources and company administration. Prior to joining Stereotaxis, Peggy served in progressive financial and administrative management positions for two software companies, CNT/Brixton Systems (SNA connectivity software) and Transparent Language (foreign language learning). She began her career as an auditor with Coopers & Lybrand in Boston, MA and is a certified public accountant. Peggy earned an M.B.A. from Washington University, St. Louis, an M.S. (Tax) from Bentley College in Waltham, Massachusetts and a B.S.B.A. in Accounting from the University of Dayton.
Brian L. Kidd, P.E., Vice President, Engineering
Brian is the Vice President, Engineering and leads the design and development of the company’s technology in preparation for clinical trials and commercialization. With nearly 20 years in the medical device field, Brian’s experience ranges from large capital equipment to high volume disposables devices. Brian began his career at Sherwood Medical (now Covidien), working on single-use safety access devices. Immediately prior to Pulse, he held a series of positions at Stereotaxis, Inc., most recently as Director of Systems Engineering. While at Stereotaxis, Brian led several multidisciplinary projects, combining hardware, software, and disposable elements, to bring the Vdrive™ Robotic Navigation platform to commercialization in markets across the globe. Brian works closely with the Regulatory team to ensure compliance with FDA and CE regulations. He holds a Bachelor’s of Science in Mechanical Engineering from Bradley University in Peoria, Illinois and a Master’s of Science in Mechanical Engineering from the Missouri University of Science & Technology. He is also a registered Professional Engineer in the state of Missouri.
Michael E. Sabo, Senior Director of Research & Development
Mike currently serves as the Senior Director of R&D for Pulse Therapeutics where he oversees the day to day RD activities for the company. He also helps to plan and run all the companies’ pre-clinical and animal study programs. From 1999 to 2009, he held various positions at Stereotaxis, Inc. (NASDAQ:STXS), including R&D Engineer and Clinical Support Specialist, and most recently as Pre-clinical Study Manager where he was responsible for all aspects of animal studies in support of regulatory submissions and clinician training. Prior to joining Stereotaxis, Michael held a faculty position at Florida State University as an Assistant in Research with the National High Magnetic Field Laboratory. He began his career as a nuclear-qualified electrical plant operator with the U. S. Navy and is a lifetime member of the Veterans of Foreign Wars. Michael earned a B. Sc. in Environmental Studies and a Certificate in Urban & Regional Planning from Florida State University.
David C. Greenspan, Ph.D, Director of Materials, Quality and Regulatory Affairs
David is currently owner of Spinode Consulting, a medical device consulting business. David has served as V.P. Product Development for Tutogen Medical and RTI Biologics, Chief Technical Officer and co-founder of NovaMin Technologies, VP Research and Development and co-founder of USBiomaterials. He began his career with Howmedica, an orthopedic implant manufacturer. He is co-inventor of the NovaMin technology, along with numerous patents for application of bioactive glasses in medicine. His educational background includes a B.S. in Glass Science from Alfred University and a Ph.D. in Materials Science from the University of Florida. He holds 36 U.S. and International patents and has published and presented scientific papers, with over 40 peer-reviewed publications and more than 65 presentations at international conferences. He is a member of the ASTM F-4 Committee on Medical Devices, as well as a past member of ISO TC 150 and 194. He served as Chairman of the External Advisory Board for the Department of Materials Science and Engineering at Pennsylvania State University and has also served on the External Advisory Board of both Biomedical Engineering and Materials Science and Engineering at the University of Florida.
Colin P. Derdeyn, M.D., Chair, Pulse Therapeutics Scientific Advisory Board
Colin is a world-renowned leader in the field of stroke. He is a professor of radiology, neurology and neurological surgery and director of the Stroke and Cerebrovascular Center at Washington University and Barnes Jewish Hospital. He received his B.A. (Echols Scholar) from the University of Virginia in 1984, and his M.D. from the University of Virginia in 1988. Dr. Derdeyn is a past president of the Society for NeuroInterventional Surgery, the national medical society for endovascular neurointervention. He is on the editorial board of Stroke. He has been active in the national committees of the American Heart Association. He is currently Vice-Chair of the Stroke Council and he is a past chair of the Stroke Council Scientific Statement Oversight Committee. Dr. Derdeyn’s practice is limited to the endovascular treatment of cerebrovascular disease, including ischemic stroke. His research is similarly focused on these areas. He has extensive experience in stroke-related clinical trials as an executive investigator. He chairs the NIH Data Safety and Monitoring Board for two randomized clinical trials of acute stroke intervention. He is the director of a large, NIH-funded, stroke research center (Specialized Programs for Translational Research in Acute Stroke (SPOTRIAS). He is an executive investigator (interventional PI) for a multi-center randomized trial of angioplasty and stenting versus medical therapy for intracranial atherosclerotic disease (SAMMPRIS). He holds several patents for devices related to aneurysm treatment. He recently completed an 8 year term as a member of the Scientific Advisory Board of W.L. Gore and Associates prior to his role of chairing the SAB for Pulse Therapeutics.
Seth Greenberg, Ph.D, Global Regulatory Affairs
Seth J. Goldenberg Ph.D., is currently a Senior Principal Scientist with NAMSA and a former member with the U.S. FDA. He holds a Ph.D. in Pharmacology from the University of Washington and a M.S. from the School of Biomedical Engineering at Drexel University. At NAMSA Dr. Goldenberg and the other 750 NAMSA associates within the premier global medical research organization, provide expert regulatory, clinical, and compliance services to medical device and healthcare product manufacturers around the world. Dr. Goldenberg understands not only what it takes to carry out scientific study, but also the importance of communicating it with the global scientific community to foster partnerships and collaboration, demonstrated by his strong publication record in such journals as Cell, Science, and Nature Cell Biology that have been cited over 800 times.
Christopher B. Reid, Outside Counsel
Chris Reid serves as outside counsel to Pulse Therapeutics and is a partner with Thompson Coburn LLP. He has extensive experience in corporate and securities law, with an emphasis on mergers and acquisitions, start-up company representations, private placements and general corporate representation. Chris and his partners have helped launch and structure companies, trademark a brand’s distinctive name and logo, structure debt and equity financings, draft commercial agreements, and respond to state and federal regulatory issues. Chris maintains a long history of serving as a strategic partner to new and growing ventures. He has received numerous accolades for his service and was recently named Lawyer of the Year for Venture Capital Law in St. Louis by Best Lawyers.®